

**REMARKS**

Claims 1, 2, and 12-18 are pending.

New claims 21-40 are added.


Applicants hereby elect to prosecute Group I, which includes and is drawn to Claims 1, 2, and 12, directed to polypeptides (before amendment). Equivalent claims in the new claim set are claims 21, 22, 36, and 37. New claims 28-29 are to a method for producing the polypeptide of claim 22. These claims generally depend from claim 22, and so should be examined as part of Group I. Applicants respectfully remind the examiner of the rules of rejoinder for method of use claims, should composition claims be allowed (MPEP 821.04).

Please charge Deposit Account No. **09-0108** in the amount of \$ **240.00** as set forth in the enclosed transmittal letter. If the USPTO determines that an additional fee is necessary, please charge any required fee to Deposit Account No. **09-0108**.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 1 May 2000



Adam Warwick Bell, D.Phil.

Reg. No. 43,490

Direct Dial Telephone: (650) 621-7542

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166